Baltic Daily Digest — 8 Jul 2026

Company Overview

Medicina Practica runs a network of private diagnostic laboratories and medical testing services exclusively in Lithuania. At an estimated €3.2 million in revenue, the platform is small by Baltic standards yet large enough to serve as a functional roll-up vehicle in a still-fragmented local testing market.

Deal Context

The transaction is positioned as a consolidation play amid rising private-equity interest in Baltic healthcare services. PE sponsors seeking a low-cost entry into Lithuania’s diagnostics segment are the most probable buyers; strategic hospital groups or larger Nordic lab operators may also view the asset as a quick capacity addition with follow-on acquisition optionality.

Valuation Context

Listed Baltic peers currently trade between 5.3x and 13.2x EV/EBITDA. Applying a 30–50 % private-company discount to reflect size, illiquidity and reimbursement exposure produces a realistic 4–7x EBITDA or 1.0–1.5x revenue range for Medicina Practica. This is consistent with the 6–8x EBITDA discount already flagged relative to higher-margin names such as Tallink and TKM.

Triage Verdict

GO

• Fit: Lithuania-based healthtech platform squarely inside the stated PE consolidation theme and at a scale that can be integrated without regulatory complexity.
• Red flags: Thin revenue base and single-country reimbursement exposure limit downside protection.
• Next step: Request a data room focused on EBITDA bridge, payer mix and capex requirements before approaching the founder.

Key Risk

Any tightening of Lithuanian public reimbursement tariffs would immediately pressure margins and reduce the attractiveness of further roll-ups.

Medicina Practica is a credible, discounted platform for Baltic lab consolidation provided reimbursement risk is contained.